Carbapenems such as imipenem and meropenem are first-line drugs in the treatment of serious infections caused by multidrug-resistant *Pseudomonas aeruginosa*, *Acinetobacter* spp., and *Enterobacteriaceae*. However, in recent years, imipenem resistance in *P. aeruginosa* and *Acinetobacter* spp. has been increasing steadily around the world, and in Korea, these resistance rates reached 22% and 64%, respectively, in 2011.[@B1] Among several mechanisms of carbapenem resistance, acquired metallo-β-lactamases (MBLs) have a more serious impact as the enzymes confer a high level of resistance and the genes can be transferred horizontally.[@B2],[@B3] Among acquired MBLs, VIM-type and IMP-type enzymes are the most common types of MBLs with worldwide distribution,[@B4] and the VIM-2 type has been highly prevalent in Korea.[@B5],[@B6] In our previous study in 2003-2004, imipenem-nonsusceptible *P. aeruginosa* isolates carrying the *bla*~VIM-2~ allele were highly prevalent, and the incidence of *Acinetobacter* spp. carrying the *bla*~VIM-2~ allele had increased compared to those carrying the *bla*~IMP-1~ allele.[@B5] The aim of the present study was to determine the trends of carbapenem-resistant and MBL-producing Gram-negative bacilli over the past 8 years in a Korean teaching hospital with more than 2000 beds. This is a unique report on the long term trend of carbapenem-resistant and MBL-producing Gram-negative bacilli isolated in a single hospital.

In total, non-duplicated clinical isolates of 12650 *P. aeruginosa*, 1096 other *Pseudomonas* spp., and 7650 *Acinetobacter* spp. in addition to 14026 *Klebsiella pneumoniae*, 6110 *Enterobacter cloacae*, and 3162 *Serratia marcescens* isolates among *Enterobacteriaceae* were recovered from patients at the hospital from 2005 to 2012 ([Table 1](#T1){ref-type="table"}). The isolates were identified by conventional methods using ATB 32 GN or VITEK-2 systems (bioMerieux, Marcy-l\'E\'toile, France). Antimicrobial susceptibilities were determined using the disk-diffusion method or the VITEK-2 system (bioMerieux). The Clinical and Laboratory Standards Institute 2010 breakpoints were used after January 2011.[@B7] The modified Hodge test (MHT) and the imipenem and ethylenediaminetetraacetic acid sodium mercaptoacetic acid double disk potentiation (IEDDP) test were conducted to screen for MBL producers in imipenem- or meropenem-nonsusceptible isolates.[@B8] Polymerase chain reaction (PCR) was performed to detect and sequence *bla*~VIM-2~-like, *bla*~IMP-1~-like and *bla*~SIM-1~-like genes.[@B9],[@B10] In carbapenem-nonsusceptible strains showing MHT-positive yet the aforementioned PCR negative results, *bla*~NDM~ and *bla*~KPC~ genes were also screened by PCR.[@B11],[@B12] The nucleotide sequences of PCR-generated amplicons were analyzed for the representative strains. XbaI- or SmaI-digested genomic DNAs from 75 *P. aeruginosa*, 8 *P. putida*, and 109 *Acinetobacter* spp., all of which were randomly selected MBL-producing spp. isolated in 2005-2006, were separated by pulsed field gel electrophoresis (PFGE) using a CHEF-DR II system (Bio-Rad, Hercules, CA, USA) and BioNumerics software v. 5.10 (Applied Maths, Sint-Martens-Latem, Belgium). PFGE banding pattern clustering with an 80% similarity threshold was determined using the Dice coefficients and the unweighted pair group method using arithmetic averages using Molecular Analyst Fingerprinting Software (Bio-Rad). Related clones with one or two independent genetic events were designated as subtype numbers in [Table 2](#T2){ref-type="table"}. The S1-digested DNA of randomly selected *P. aeruginosa*, *Pseudomonas putida*, and *Acinetobacter* spp. strains carrying the *bla*~VIM-2~ allele were blotted onto nylon membranes (Bio-Rad) and hybridized with *bla*~VIM-2~ gene probes to observe the differences in the plasmids carrying the gene.

While annual imipenem resistance rates in *P. aeruginosa* increased from 14% in 2003 to 29% in 2009, they decreased from 58% in 2003 to 33% in 2012 in other *Pseudomonas* spp.; in *Acinetobacter* spp., resistance rates increased steeply from 13% in 2003 to 66% in 2012.[@B5] However, the imipenem resistance rates in *K. pneumoniae*, *E. cloacae*, and *S. marcescens* isolates remained at less than 1%. The positive rates of MHT were highly variable depending on the species, being only 13% in *P. aeruginosa* isolates, yet reaching 69% in other *Pseudomonas* spp. and 94% in *Acinetobacter* spp. These findings suggest that the majority of other *Pseudomonas* and *Acinetobacter* spp. isolates clearly produced the carbapenem-hydrolyzing enzymes to gain their resistance to carbapenem, while *P. aeruginosa* isolates obtained other resistance mechanisms such as AmpC or extended spectrum β-lactamase and porin loss, as previously reported.[@B13],[@B14]

Among the carbapenem-nonsusceptible isolates, MBL producers included only 6% (243 of 4077) of *P. aeruginosa* spp. and only 7% (262 of 3998) of *Acinetobacter* spp. Interestingly, 157 of 247 (64%) of the other *Pseudomonas* spp. produced MBL, and almost all of them (152 of 157) were *P. putida*, which was a much higher incidence than those of the other species. These findings suggest that *P. putida* can be a reservoir for MBL, as previously described.[@B15] *Acinetobacter* spp. with different carbapenem-resistance mechanisms, such as OXA-type β-lactamases, have become prevalent.[@B16]

In *P. aeruginosa*, the incidence of MBL producers increased until the mid-2000s in this study, as shown in Japan,[@B17] while in more recent years, these isolates gradually decreased in this study, as described in a previous report.[@B18] Likewise, Cavalcanti, et al.[@B19] reported that a higher prevalence of MBL-producing *P. aeruginosa* was observed in 2002-2003 in Brazil, while the level decreased significantly in 2008-2009, suggesting that the resistance to carbapenems by these recent *P. aeruginosa* isolates was not due to the spread of MBL-positive clones. In this study, *P. aeruginosa* isolates carrying a *bla*~VIM-2~-like gene were highly prevalent, comprising 90% to 100% of the *P. aeruginosa* strains in 2003 to 2004,[@B5] although they were reduced to 34% while those with *bla*~IMP-1~-like genes increased to 69% in 2010.

Among MBL-producing *Acinetobacter* spp. isolates, the prevalence of *bla*~IMP-1~-like genes also increased to 85% in 2012. The range of strains carrying *bla*~SIM-1~-like genes remained low. Two isolates carrying *bla*~NDM-1~-like genes that were isolated in 2011 were identified as *A. pitti* and *A. guillouiae*. To our knowledge, this is the first report of a clinical isolate of *A. guillouiae* carrying the *bla*~NDM-1~-like gene. Most of the other *Pseudomonas* spp. isolates carrying MBL genes were identified as *P. putida*, and their MBL genes were *bla*~VIM-2~-like.

Among the 254 carbapenem-nonsusceptible *Enterobacteriaceae*, only five isolates, two *K. pneumoniae*, two *E. cloacae*, and one *S. marcescens*, produced MBL, suggesting that the major carbapenem resistance mechanism in *Enterobacteriaceae* was not MBL. Our results support previous reports that suggested that carbapenem resistance in *Enterobacteriaceae* was comediated with AmpC beta-lactamase and outer membrane protein loss in *K. pneumoniae*, *E. cloacae*, and *S. marcescens*.[@B20],[@B21],[@B22]

PFGE analysis revealed that the pulsotypes of IMP-6- and VIM-2-producing *P. aeruginosa* strains were clearly separated. The major pulsotypes in the IMP-6-producing *P. aeruginosa* were A2 and A3, while those in the VIM-2-producing *P. aeruginosa* were A1 and C1 types ([Table 2](#T2){ref-type="table"}). Likewise, the pulsotypes of *Acinetobacter* spp. isolates obviously differed according to MBL type ([Table 2](#T2){ref-type="table"}). These findings suggest that the plasmids carrying the MBL gene are not promiscuous, although they do have clone preference. Interestingly, *Acinetobacter* spp. isolates in the E1, H1, I4, J3, N1, and Q subgroups showed identical PFGE patterns, despite the differences in species. This suggests that the identification of *Acinetobacter* species is important for evaluating clonal outbreaks in hospital settings, as the misinterpretation of a clonal outbreak occurred among the different species.

Other mechanisms may block the cross-over of resistance plasmids between clones. Further study is warranted to elucidate this supposition. The hybridization of S1-digested DNA showed that the sizes of *bla*~VIM-2~ gene-carrying plasmids in *P. aeruginosa*, *P. putida*, and *Acinetobacter* spp. isolates were diverse ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}, only online). It is noteworthy that the *bla*~VIM-2~ gene-carrying plasmids in *Acinetobacter* spp. were in multimer forms, indicating that the plasmids did not replicate themselves in the same way as with *P. aeruginosa*. Further plasmid sequence analysis using massive parallel sequencing technology has been undertaken.

In conclusion, MBL-producing clinical isolates of *P. aeruginosa* and *Acinetobacter* spp. were reduced, and carbapenemase-producing *Enterobacteriaceae* were found to be rare in Korea. Continuous surveillance studies and further deep sequencing are necessary to understand the dissemination mechanism of the carbapenem-nonsusceptible Gram-negative bacilli isolates in order to control their spread.
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###### Supplementary Fig. 1.

\(A\) Pulsed field gel electrophoresis of whole genomic DNA of VIM-2-producing *P. aeruginosa* (lanes 2 to 16), *P. putida* (lanes 17 to 22), and *Acinetobacter* spp. isolates (lanes 23 to 27) digested with S1 nuclease. (B) Southern blot hybridization with *bla*~VIM-2~ gene probe. Lane M, lambda ladder (Bio-Rad) as a marker (kb). The genomic DNA of *P. aeruginosa* stains with high endogenous DNase activities were degraded not to show positive bands (lanes 2, 3, 4, 6, 7, 8, 9, 11, 12, 13, and 15).
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Annual Imipenem Resistance Rates and MBL-Producing Clinical Isolates over 8 Years
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MBL, metallo-β-lactamase.

^\*^Both *bla*~VIM-2~-like and *bla*~IMP-1~-like genes were detected in two isolates in 2006 and one isolate per year in 2007, 2010, and 2012.

^†^Both a *bla*~VIM-2~-like gene and a *bla*~SIM-1~-like gene were detected in one isolate.

^‡^An ~NDM-1~ gene was detected in two isolates.

###### 

Pulsotypes of 109 MBL-Producing *Acinetobacter* spp. and 75 *P. aeruginosa* Isolates

![](ymj-56-572-i002)

e, each; MBL, metallo-β-lactamase.

^\*^*A. johnsonii* (n=2), *A. baumannii* (n=1), *A. baylyi* (n=1), *A. soli* (n=1), *A. ursingii* (n=1).
